

## TABLE OF CONTENTS

APPROVAL PAGE .....	ii
AUTHENTICITY STATEMENT .....	iii
PREFACE .....	iv
TABLE OF CONTENTS .....	vi
LIST OF TABLES .....	ix
LIST OF FIGURES .....	x
LIST OF ATTACHMENT .....	xi
LIST OF ABBREVIATIONS .....	xii
ABSTRACT .....	xiii
CHAPTER 1 INTRODUCTION .....	1
1.1 Background .....	1
1.2 Problem Formulation .....	1
1.3 Study Objective .....	2
1.4 Study Authenticity .....	2
1.5 Study Benefit .....	4
CHAPTER 2 LITERATURE REVIEW .....	5
2.1 Epidemiology .....	5
2.2 Risk Factors .....	6
a) Hepatitis Virus .....	6
b) Aflatoxin B1 .....	7
c) Alcohol .....	7
d) Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis .....	8
e) Obesity, Diabetes Mellitus, and Metabolic Syndrome .....	8
2.3 Pathogenesis .....	9
2.4 Clinical Manifestation .....	10
a) Hemoglobin .....	10
b) Thrombocyte .....	11
c) Albumin .....	11
d) AFP .....	11

e) Aspartate Aminotransferase and Alanine Aminotransaminase .....	12
2.5 Staging and Scoring .....	12
a) OKUDA Staging System .....	13
b) Cancer of the Liver Italian Program Score (CLIP) .....	14
c) Barcelona Clinic Liver Cancer Classification (BCLC) .....	15
d) AJCC/TNM 7 <sup>th</sup> Edition .....	17
e) Chines University Prognostic Index (CUPI) .....	17
f) Japan Integrated Staging (JIS) .....	18
g) Tokyo Score .....	19
h) Advanced Liver Cancer Prognostic System (ALCPS) .....	20
2.6 Therapy and Management .....	21
2.7 Prognosis .....	22
2.8 Theoretical Framework .....	23
2.9 Conceptual Framework .....	23
CHAPTER 3 RESEARCH METHOD .....	24
3.1 Research Design .....	24
3.2 Research Time and Place .....	24
3.3 Research Population .....	24
3.4 Research Subject .....	24
3.5 Research Sample .....	24
3.6 Research Variable .....	25
3.7 Operational Definition on Research Variable .....	26
3.8 Study Instruments .....	27
3.9 Sample Size .....	27
3.10 Study Plan .....	27
CHAPTER IV RESULT AND DISCUSSION .....	29
4.1 Age .....	30
4.2 Gender .....	30
4.3 Education Level .....	31
4.4 Etiology .....	31
4.5 Underlying Disease .....	32

4.6 Blood Panel and Biomarkers .....	33
a) Hemoglobin and Thrombocyte .....	33
b) Albumin .....	34
c) Alpha Fetoprotein (AFP) .....	34
d) Aspartate Aminotransferase and Alanine Aminotransferase .....	34
4.7 BCLC Staging .....	36
4.8 Okuda Staging .....	37
4.9 CLIP Score .....	38
STUDY LIMITATION .....	38
CHAPTER V CONCLUSION AND SUGGESTIONS .....	39
5.1 Conclusion .....	39
5.2 Suggestions .....	39
REFERENCES .....	41

## LIST OF TABLES

<b>Table 1.</b> Study authenticity .....	3
<b>Table 2.</b> Okuda Staging System .....	14
<b>Table 3.</b> Cancer of the Liver Italian Program (CLIP) .....	15
<b>Table 4.</b> American Joint Committee on Cancer/TNM7 <sup>th</sup> edition .....	17
<b>Table 5.</b> Chines University Prognostic Index .....	18
<b>Table 6.</b> Japan Integrated Staging .....	19
<b>Table 7.</b> Tokyo Score .....	20
<b>Table 8.</b> Advanced Liver Cancer Prognostic Program .....	21
<b>Table 9.</b> Operational definitions .....	26
<b>Table 10.</b> Demographic and Clinical results .....	29
<b>Table 11.</b> Hepatitis Infection with Diabetes .....	32
<b>Table 12.</b> Blood Panel and Biomarker Result .....	33
<b>Table 13.</b> Classification result .....	35

## LIST OF FIGURES

<b>Figure 1.</b> Barcelona Clinic Liver Cancer Classification .....	16
<b>Figure 2.</b> Theoretical framework .....	23
<b>Figure 3.</b> Conceptual framework .....	23
<b>Figure 4.</b> Study Plan .....	28
<b>Figure 5.</b> BCLC Staging Result .....	36
<b>Figure 6.</b> Okuda Staging Result .....	37
<b>Figure 7.</b> CLIP Score Result .....	38

## **LIST OF ATTACHMENT**

<b>Attachment 1.</b> Ethical Clearance .....	45
--	----